Home
Company
Leadership
Approach
Science & Pipeline
Resources
Investors
News & Events
Contact
News and Events
Home
News and Events
News and Events
February 13, 2024
First Patient Dosed in Phase 2a Psoriasis Trial
January 4, 2024
Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 Year
November 9, 2023
Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study
June 1, 2023
Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases
March 7, 2023
Artax Biopharma Appoints Andre Hoekema Ph.D to the Company’s Board of Directors
November 15, 2022
Artax Biopharma Expands Company’s Scientific Advisory Board
June 29, 2022
Artax Biopharma Appoints D. Scott Batty, Jr., M.D. as Chief Medical Officer
May 11, 2022
Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
December 15, 2021
Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158
July 13, 2021
Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158
September 17, 2020
Artax Biopharma Announces Issuance of U.S. Composition of Matter Patent for Autoimmune Disease Program AX-158
June 24, 2020
Artax Biopharma Announces the Formation of Scientific Advisory
Board to Advance Autoimmune Disease Therapy AX-158
June 4, 2020
Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy
May 13, 2020
Artax Biopharma Appoints Joseph Lobacki as Chief Executive Officer, Announces Expanded Management Team